NCT04892017 2026-04-08
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1 Terminated
Clinical Trials
19 trialsNCT05355701 2026-03-27
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT04913285 2025-12-24
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Pierre Fabre Medicament
Phase 1 Active not recruiting
NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT03374254 2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04800822 2024-10-22
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03864042 2024-09-27
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT04965818 2024-09-19
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Taiho Oncology, Inc.
Phase 1 Terminated
NCT05810740 2024-09-19
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
Pierre Fabre Medicament
Phase 1 Completed
NCT03878719 2023-04-03
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
Pfizer
Phase 1 Terminated
NCT04759846 2023-02-21
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Pierre Fabre Medicament
Phase 1 Withdrawn
NCT05103891 2021-12-01
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
Pierre Fabre Medicament
Phase 1 Unknown
NCT01337765 2020-10-09
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Pfizer
Phase 1 Completed
NCT01363232 2020-10-05
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Array BioPharma
Phase 1 Completed
NCT01469130 2020-10-05
A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
Array BioPharma
Phase 1 Completed
NCT01352273 2020-09-30
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
Array BioPharma
Phase 1 Completed
NCT00959127 2020-09-16
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT01649336 2020-09-14
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Array BioPharma
Phase 1 Completed
NCT01449058 2017-10-02
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Array BioPharma
Phase 1 Completed